Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 5.5% - Here's What Happened

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) dropped 5.5% on Thursday . The company traded as low as $12.87 and last traded at $13.11. Approximately 12,683 shares were traded during trading, a decline of 95% from the average daily volume of 237,319 shares. The stock had previously closed at $13.87.

Analyst Upgrades and Downgrades

MAZE has been the subject of a number of recent analyst reports. TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 25th. Guggenheim reissued a "buy" rating and set a $19.00 price target on shares of Maze Therapeutics in a research report on Wednesday, April 2nd. Leerink Partnrs raised shares of Maze Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 25th. JPMorgan Chase & Co. started coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set an "overweight" rating and a $30.00 price target for the company. Finally, Leerink Partners began coverage on Maze Therapeutics in a research report on Tuesday, February 25th. They issued an "outperform" rating and a $28.00 target price for the company. Three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $25.67.

Maze Therapeutics Price Performance

The stock's 50 day moving average is $9.67.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).

Hedge Funds Weigh In On Maze Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. TRV GP IV LLC acquired a new position in Maze Therapeutics during the 1st quarter valued at about $66,874,000. Frazier Life Sciences Management L.P. acquired a new position in Maze Therapeutics during the 1st quarter valued at about $45,460,000. ARCH Venture Management LLC acquired a new position in Maze Therapeutics during the 1st quarter valued at about $45,362,000. Matrix Capital Management Company LP acquired a new position in Maze Therapeutics during the 1st quarter worth $27,373,000. Finally, Alphabet Inc. acquired a new position in Maze Therapeutics during the 1st quarter worth $26,561,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.